{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:45:10Z","timestamp":1761561910628},"reference-count":36,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The objective of this study was to estimate the direct financial costs of hospital care for management of invasive group A streptococcal (GAS) infections using hospital records for cases diagnosed in England. We linked laboratory-confirmed cases (<jats:italic>n<\/jats:italic>= 3696) identified through national surveillance to hospital episode statistics and reimbursement codes. From these codes we estimated the direct hospital costs of admissions. Almost all notified invasive GAS cases (92% of 3696) were successfully matched to a primary hospital admission. Of these, secondary admissions (within 30 days of primary admission) were further identified for 593 (17%). After exclusion of nosocomial cases (12%), the median costs of primary and secondary hospital admissions were estimated by subgroup analysis as \u00a31984\u2013\u00a32212 per case, totalling \u00a34\u00b743\u2013\u00a36\u00b734 million per year in England. With adjustment for unmatched cases this equated to \u00a34\u00b784\u2013\u00a36\u00b793 million per year. Adults aged 16\u201364 years accounted for 48% of costs but only 40% of cases, largely due to an increased number of surgical procedures. The direct costs of hospital admissions for invasive GAS infection are substantial. These estimated costs will contribute to a full assessment of the total economic burden of invasive GAS infection as a means to assess potential savings through prevention measures.<\/jats:p>","DOI":"10.1017\/s0950268814002489","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T10:43:17Z","timestamp":1411987397000},"page":"1719-1730","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":12,"title":["The cost of hospital care for management of invasive group A streptococcal infections in England"],"prefix":"10.1017","volume":"143","author":[{"given":"G. J.","family":"HUGHES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"VAN HOEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"SRISKANDAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L.","family":"LAMAGNI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,9,29]]},"reference":[{"key":"S0950268814002489_ref7","doi-asserted-by":"publisher","DOI":"10.3201\/eid1508.090264"},{"key":"S0950268814002489_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70190-0"},{"key":"S0950268814002489_ref23","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.518135"},{"key":"#cr-split#-S0950268814002489_ref27.1","unstructured":"1. Health Protection Agency. Cessation of enhanced data collection for invasive group A streptococcal disease. Health Protection Report 2010"},{"key":"#cr-split#-S0950268814002489_ref27.2","unstructured":"2. (http:\/\/www.hpa.org.uk\/hpr\/archives\/2010\/news0310.htm). Accessed 4 April 2013."},{"key":"S0950268814002489_ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-109"},{"key":"S0950268814002489_ref24","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.048421"},{"key":"S0950268814002489_ref28","unstructured":"Department of Health. Payment by results guidance for 2010\u201311. 2010 (http:\/\/collections.europarchive.org\/tna\/20100509080731\/http:\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/documents\/digitalasset\/dh_112970.pdf). Accessed 7 January 2014."},{"key":"S0950268814002489_ref31","first-page":"1","article-title":"Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2005","journal-title":"British Medical Journal"},{"key":"S0950268814002489_ref22","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903583404"},{"key":"S0950268814002489_ref19","first-page":"U933","article-title":"Economic cost of community-acquired pneumonia in New Zealand adults","volume":"117","author":"Scott","year":"2004","journal-title":"New Zealand Medical Journal"},{"key":"S0950268814002489_ref2","first-page":"202","article-title":"Severe Streptococcus pyogenes infections, United Kingdom, 2003\u20132004","volume":"14","author":"Lamagni","year":"2008","journal-title":"Epidemiology and Infection"},{"key":"S0950268814002489_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdr054"},{"key":"S0950268814002489_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70178-1"},{"key":"S0950268814002489_ref13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0484"},{"key":"S0950268814002489_ref25","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.774278"},{"key":"S0950268814002489_ref35","first-page":"243","article-title":"Clinical management of the most common group A \u03b2-hemolytic streptococcal infections","volume":"368","author":"Kaplan","year":"2013","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"S0950268814002489_ref26","unstructured":"Department of Health. 2010\u201311 National Tariff Information. 2010 (http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_112284). Accessed 15 January 2013."},{"key":"S0950268814002489_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/0163-4453(93)93112-H"},{"key":"S0950268814002489_ref5","doi-asserted-by":"publisher","DOI":"10.1086\/521264"},{"key":"S0950268814002489_ref11","doi-asserted-by":"publisher","DOI":"10.1086\/656214"},{"key":"S0950268814002489_ref16","first-page":"21","article-title":"Factors associated with length of stay and hospital charges for patients hospitalized with mouth cellulitis","volume":"113","author":"Kim","year":"2012","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"key":"S0950268814002489_ref1","first-page":"1","article-title":"Group A streptococcal diseases and their global burden","volume":"368","author":"Ralph","year":"2013","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"S0950268814002489_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)50887-8"},{"key":"S0950268814002489_ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01169.x"},{"key":"S0950268814002489_ref3","doi-asserted-by":"publisher","DOI":"10.2165\/11634180-000000000-00000"},{"key":"S0950268814002489_ref4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5694\/j.1326-5377.2007.tb01054.x","article-title":"The epidemiology of invasive group A streptococcal disease in Victoria, Australia","volume":"186","author":"O'Grady","year":"2007","journal-title":"Medical Journal of Australia"},{"key":"S0950268814002489_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.056"},{"key":"S0950268814002489_ref12","first-page":"207","article-title":"Group A streptococcal vaccine candidates: potential for the development of a human vaccine","volume":"368","author":"Henningham","year":"2013","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"S0950268814002489_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.051"},{"key":"S0950268814002489_ref9","unstructured":"World Health Organisation. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. 2005 (http:\/\/www.who.int\/maternal_child_adolescent\/documents\/ivb_05_14\/en). Accessed 4 July 2014."},{"key":"S0950268814002489_ref6","doi-asserted-by":"publisher","DOI":"10.3201\/eid\/1706.100804"},{"key":"S0950268814002489_ref14","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0167"},{"key":"S0950268814002489_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1650-z"},{"key":"S0950268814002489_ref17","doi-asserted-by":"publisher","DOI":"10.1136\/adc.83.4.313"},{"key":"S0950268814002489_ref34","unstructured":"NHS Information Centre for Health and Social Care. Adult critical care in England\u2013April 2010 to March 2011: Experimental statistics (http:\/\/www.ic.nhs.uk\/catalogue\/PUB06193\/adul-crit-care-data-eng-apr-10-mar-11-rep.pdf). Accessed 29 April 2013."}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268814002489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T03:10:18Z","timestamp":1598325018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268814002489\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,29]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0950268814002489"],"URL":"https:\/\/doi.org\/10.1017\/s0950268814002489","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,29]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2014\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}